|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:GSK3B-ARNT (FusionGDB2 ID:HG2932TG405) |
Fusion Gene Summary for GSK3B-ARNT |
Fusion gene summary |
Fusion gene information | Fusion gene name: GSK3B-ARNT | Fusion gene ID: hg2932tg405 | Hgene | Tgene | Gene symbol | GSK3B | ARNT | Gene ID | 2932 | 405 |
Gene name | glycogen synthase kinase 3 beta | aryl hydrocarbon receptor nuclear translocator | |
Synonyms | - | HIF-1-beta|HIF-1beta|HIF1-beta|HIF1B|HIF1BETA|TANGO|bHLHe2 | |
Cytomap | ('GSK3B')('ARNT') 3q13.33 | 1q21.3 | |
Type of gene | protein-coding | protein-coding | |
Description | glycogen synthase kinase-3 betaGSK-3 betaGSK3beta isoformserine/threonine-protein kinase GSK3B | aryl hydrocarbon receptor nuclear translocatorclass E basic helix-loop-helix protein 2dioxin receptor, nuclear translocatorhypoxia-inducible factor 1, beta subunit | |
Modification date | 20200315 | 20200315 | |
UniProtAcc | P49841 | . | |
Ensembl transtripts involved in fusion gene | ENST00000264235, ENST00000316626, ENST00000473886, | ||
Fusion gene scores | * DoF score | 31 X 22 X 12=8184 | 9 X 6 X 6=324 |
# samples | 36 | 9 | |
** MAII score | log2(36/8184*10)=-4.50673733341565 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/324*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: GSK3B [Title/Abstract] AND ARNT [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | GSK3B(119582266)-ARNT(150790506), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | GSK3B-ARNT seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. GSK3B-ARNT seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. GSK3B-ARNT seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. GSK3B-ARNT seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. GSK3B-ARNT seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | GSK3B | GO:0005977 | glycogen metabolic process | 8638126 |
Hgene | GSK3B | GO:0006468 | protein phosphorylation | 11035810|16315267|20937854 |
Hgene | GSK3B | GO:0006983 | ER overload response | 14744935 |
Hgene | GSK3B | GO:0018105 | peptidyl-serine phosphorylation | 8638126|11104755|11955436|14744935|17139249 |
Hgene | GSK3B | GO:0018107 | peptidyl-threonine phosphorylation | 11955436|17139249|25897075 |
Hgene | GSK3B | GO:0031175 | neuron projection development | 19830702 |
Hgene | GSK3B | GO:0031334 | positive regulation of protein complex assembly | 8638126 |
Hgene | GSK3B | GO:0032091 | negative regulation of protein binding | 16890161 |
Hgene | GSK3B | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 19364825 |
Hgene | GSK3B | GO:0035556 | intracellular signal transduction | 14749367 |
Hgene | GSK3B | GO:0043066 | negative regulation of apoptotic process | 14744935 |
Hgene | GSK3B | GO:0046777 | protein autophosphorylation | 23184662 |
Hgene | GSK3B | GO:0046827 | positive regulation of protein export from nucleus | 14744935 |
Hgene | GSK3B | GO:1901215 | negative regulation of neuron death | 19830702 |
Hgene | GSK3B | GO:1901216 | positive regulation of neuron death | 18508033 |
Hgene | GSK3B | GO:2000300 | regulation of synaptic vesicle exocytosis | 17989287 |
Tgene | ARNT | GO:0001666 | response to hypoxia | 8756616 |
Tgene | ARNT | GO:0010575 | positive regulation of vascular endothelial growth factor production | 8756616 |
Tgene | ARNT | GO:0043619 | regulation of transcription from RNA polymerase II promoter in response to oxidative stress | 8089148 |
Tgene | ARNT | GO:0045893 | positive regulation of transcription, DNA-templated | 8089148 |
Tgene | ARNT | GO:0046886 | positive regulation of hormone biosynthetic process | 1448077 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | PRAD | TCGA-EJ-7783-01A | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Top |
Fusion Gene ORF analysis for GSK3B-ARNT |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5CDS-intron | ENST00000264235 | ENST00000468970 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5CDS-intron | ENST00000316626 | ENST00000468970 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5UTR-3CDS | ENST00000473886 | ENST00000354396 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5UTR-3CDS | ENST00000473886 | ENST00000358595 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5UTR-3CDS | ENST00000473886 | ENST00000505755 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5UTR-3CDS | ENST00000473886 | ENST00000515192 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
5UTR-intron | ENST00000473886 | ENST00000468970 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000264235 | ENST00000354396 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000264235 | ENST00000358595 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000264235 | ENST00000505755 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000264235 | ENST00000515192 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000316626 | ENST00000354396 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000316626 | ENST00000358595 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000316626 | ENST00000505755 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
Frame-shift | ENST00000316626 | ENST00000515192 | GSK3B | chr3 | 119582266 | - | ARNT | chr1 | 150790506 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for GSK3B-ARNT |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for GSK3B-ARNT |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:119582266/:150790506) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
GSK3B | . |
FUNCTION: Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2 (PubMed:19946213, PubMed:28903391). Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation (PubMed:19946213). Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation (PubMed:28903391). Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509). Regulates the circadian rhythmicity of hippocampal long-term potentiation and ARNTL/BMLA1 and PER2 expression (By similarity). Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer (PubMed:30704899). Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation (PubMed:18846110). {ECO:0000250|UniProtKB:Q9WV60, ECO:0000269|PubMed:11430833, ECO:0000269|PubMed:12554650, ECO:0000269|PubMed:14690523, ECO:0000269|PubMed:15448698, ECO:0000269|PubMed:15647282, ECO:0000269|PubMed:16484495, ECO:0000269|PubMed:18348280, ECO:0000269|PubMed:1846781, ECO:0000269|PubMed:18846110, ECO:0000269|PubMed:19946213, ECO:0000269|PubMed:20932480, ECO:0000269|PubMed:20937854, ECO:0000269|PubMed:22514281, ECO:0000269|PubMed:24391509, ECO:0000269|PubMed:28903391, ECO:0000269|PubMed:30704899, ECO:0000269|PubMed:8397507, ECO:0000269|PubMed:9072970, ECO:0000269|PubMed:9819408}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for GSK3B-ARNT |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for GSK3B-ARNT |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for GSK3B-ARNT |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | GSK3B | P49841 | DB14507 | Lithium citrate | Small molecule | Approved | |
Hgene | GSK3B | P49841 | DB14509 | Lithium carbonate | Small molecule | Approved | |
Hgene | GSK3B | P49841 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for GSK3B-ARNT |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | GSK3B | C0005586 | Bipolar Disorder | 6 | CTD_human;PSYGENET |
Hgene | GSK3B | C0011581 | Depressive disorder | 5 | CTD_human;PSYGENET |
Hgene | GSK3B | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
Hgene | GSK3B | C0011570 | Mental Depression | 3 | PSYGENET |
Hgene | GSK3B | C0002395 | Alzheimer's Disease | 2 | CTD_human |
Hgene | GSK3B | C0011265 | Presenile dementia | 2 | CTD_human |
Hgene | GSK3B | C0011573 | Endogenous depression | 2 | CTD_human |
Hgene | GSK3B | C0025193 | Melancholia | 2 | CTD_human |
Hgene | GSK3B | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Hgene | GSK3B | C0036341 | Schizophrenia | 2 | CTD_human |
Hgene | GSK3B | C0041696 | Unipolar Depression | 2 | CTD_human |
Hgene | GSK3B | C0086133 | Depressive Syndrome | 2 | CTD_human |
Hgene | GSK3B | C0276496 | Familial Alzheimer Disease (FAD) | 2 | CTD_human |
Hgene | GSK3B | C0282126 | Depression, Neurotic | 2 | CTD_human |
Hgene | GSK3B | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
Hgene | GSK3B | C0494463 | Alzheimer Disease, Late Onset | 2 | CTD_human |
Hgene | GSK3B | C0525045 | Mood Disorders | 2 | PSYGENET |
Hgene | GSK3B | C0546126 | Acute Confusional Senile Dementia | 2 | CTD_human |
Hgene | GSK3B | C0750900 | Alzheimer's Disease, Focal Onset | 2 | CTD_human |
Hgene | GSK3B | C0750901 | Alzheimer Disease, Early Onset | 2 | CTD_human |
Hgene | GSK3B | C0000772 | Multiple congenital anomalies | 1 | CTD_human |
Hgene | GSK3B | C0003865 | Arthritis, Adjuvant-Induced | 1 | CTD_human |
Hgene | GSK3B | C0005587 | Depression, Bipolar | 1 | CTD_human |
Hgene | GSK3B | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
Hgene | GSK3B | C0009241 | Cognition Disorders | 1 | CTD_human |
Hgene | GSK3B | C0018800 | Cardiomegaly | 1 | CTD_human |
Hgene | GSK3B | C0018801 | Heart failure | 1 | CTD_human |
Hgene | GSK3B | C0018802 | Congestive heart failure | 1 | CTD_human |
Hgene | GSK3B | C0020538 | Hypertensive disease | 1 | CTD_human |
Hgene | GSK3B | C0022660 | Kidney Failure, Acute | 1 | CTD_human |
Hgene | GSK3B | C0023212 | Left-Sided Heart Failure | 1 | CTD_human |
Hgene | GSK3B | C0024713 | Manic Disorder | 1 | CTD_human |
Hgene | GSK3B | C0026846 | Muscular Atrophy | 1 | CTD_human |
Hgene | GSK3B | C0027051 | Myocardial Infarction | 1 | CTD_human |
Hgene | GSK3B | C0031154 | Peritonitis | 1 | CTD_human |
Hgene | GSK3B | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human |
Hgene | GSK3B | C0270948 | Neurogenic Muscular Atrophy | 1 | CTD_human |
Hgene | GSK3B | C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | CTD_human |
Hgene | GSK3B | C0338831 | Manic | 1 | CTD_human |
Hgene | GSK3B | C0751958 | Lymphoma, Lymphocytic, Intermediate | 1 | CTD_human |
Hgene | GSK3B | C0949664 | Tauopathies | 1 | CTD_human |
Hgene | GSK3B | C0971858 | Arthritis, Collagen-Induced | 1 | CTD_human |
Hgene | GSK3B | C0993582 | Arthritis, Experimental | 1 | CTD_human |
Hgene | GSK3B | C1383860 | Cardiac Hypertrophy | 1 | CTD_human |
Hgene | GSK3B | C1449646 | Primary Peritonitis | 1 | CTD_human |
Hgene | GSK3B | C1449647 | Secondary Peritonitis | 1 | CTD_human |
Hgene | GSK3B | C1565662 | Acute Kidney Insufficiency | 1 | CTD_human |
Hgene | GSK3B | C1866282 | CEROID LIPOFUSCINOSIS, NEURONAL, 6 | 1 | CTD_human |
Hgene | GSK3B | C1959583 | Myocardial Failure | 1 | CTD_human |
Hgene | GSK3B | C1961112 | Heart Decompensation | 1 | CTD_human |
Hgene | GSK3B | C2609414 | Acute kidney injury | 1 | CTD_human |
Tgene | C0000786 | Spontaneous abortion | 1 | CTD_human | |
Tgene | C0000822 | Abortion, Tubal | 1 | CTD_human | |
Tgene | C0009402 | Colorectal Carcinoma | 1 | CTD_human | |
Tgene | C0009404 | Colorectal Neoplasms | 1 | CTD_human | |
Tgene | C0014175 | Endometriosis | 1 | CTD_human | |
Tgene | C0019193 | Hepatitis, Toxic | 1 | CTD_human | |
Tgene | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human | |
Tgene | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human | |
Tgene | C0023890 | Liver Cirrhosis | 1 | CTD_human | |
Tgene | C0025202 | melanoma | 1 | CTD_human | |
Tgene | C0027659 | Neoplasms, Experimental | 1 | CTD_human | |
Tgene | C0239946 | Fibrosis, Liver | 1 | CTD_human | |
Tgene | C0269102 | Endometrioma | 1 | CTD_human | |
Tgene | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human | |
Tgene | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human | |
Tgene | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human | |
Tgene | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human | |
Tgene | C3830362 | Early Pregnancy Loss | 1 | CTD_human | |
Tgene | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human | |
Tgene | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human | |
Tgene | C4552766 | Miscarriage | 1 | CTD_human |